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Abstract
Tauopathies, including Alzheimer’s disease (AD) and frontotemporal lobar degeneration with Tau pathology (FTLD-tau), 
are a group of neurodegenerative disorders characterized by Tau hyperphosphorylation. Post-translational modifications of 
Tau such as phosphorylation and truncation have been demonstrated to be an essential step in the molecular pathogenesis 
of these tauopathies. In this work, we demonstrate the existence of a new, human-specific truncated form of Tau generated 
by intron 12 retention in human neuroblastoma cells and, to a higher extent, in human RNA brain samples, using qPCR and 
further confirming the results on a larger database of human RNA-seq samples. Diminished protein levels of this new Tau 
isoform are found by Westernblotting in Alzheimer’s patients’ brains (Braak I n = 3; Braak II n = 6, Braak III n = 3, Braak IV 
n = 1, and Braak V n = 10, Braak VI n = 8) with respect to non-demented control subjects (n = 9), suggesting that the lack of 
this truncated isoform may play an important role in the pathology. This new Tau isoform exhibits similar post-transcriptional 
modifications by phosphorylation and affinity for microtubule binding, but more interestingly, is less prone to aggregate than 
other Tau isoforms. Finally, we present evidence suggesting this new Tau isoform could be linked to the inhibition of GSK3β, 
which would mediate intron 12 retention by modulating the serine/arginine rich splicing factor 2 (SRSF2). Our results show 
the existence of an important new isoform of Tau and suggest that further research on this less aggregation-prone Tau may 
help to develop future therapies for Alzheimer’s disease and other tauopathies.
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Introduction
Tau is a microtubule-associated protein (MAP) that acts as 
a neurite microtubule stabilizer [9, 61]. Tau overexpression, 
especially in its modified forms (i.e. phosphorylated, aggre-
gated or truncated) may result in a toxic gain of function [5]. 
Human Tau protein isoforms are expressed from a unique gene 
(MAPT) located at chromosome 17 [30, 42] and has at least 
16 exons [2, 3]. Exons 1, 4, 5, 7, 9, 11, 12 and 13 are constitu-
tive while the others are subjected to alternative splicing [2, 
60]. Importantly, over 90% of human genes allegedly undergo 
alternative splicing [59], although recent evidence point out 
that this may not be the main mechanism to explain proteome 
complexity [55]. However, there is robust evidence for certain 
genes being subjected to alternative splicing, yielding well-
studied spliced variants, being MAPT one of the most relevant 
[1, 55]. Noteworthy, aberrant splicing has been associated with 
numerous diseases, including Alzheimer’s disease and other 
age-related disorders [51]. In accordance with that, mutations 
altering alternative splicing of exon 10 of MAPT cause some 
tauopathies, including FTDP-17 [16, 25, 32], and may be asso-
ciated with others such as Huntington’s disease, whose patients 
display a four-repeat tauopathy with nuclear rods [19].
Truncated Tau proteins lead to a toxic gain of function, 
promoting abnormal microtubule assembly and inducing 
aggregation, being a key feature of Alzheimer’s disease, 
especially in the sporadic form [43, 65].
Tau truncation can take place at N-terminal or C-terminal 
regions [6, 22, 41, 44, 46, 48, 52, 63, 64]. Recently, a trun-
cated toxic Tau fragment raised upon asparagine endopepti-
dase (AEP) cleavage, has been reported in mice model of 
AD and elderly and Alzheimer’s disease human brains [63]. 
This toxic fragment contains residues 1–368 of the human 
Tau molecule and the last residue (asparagine 368) coincides 
with the end of exon 12.
Here, we present evidence of a new, human-specific trun-
cated form of Tau similar to Tau 1–368 generated by intron 
12 retention in human neuroblastoma cell lines and brain. 
An analogous mechanism of truncation has been described 
for a toxic huntingtin fragment [52]. This intron-retaining 
RNA species would generate a truncated Tau protein similar 
to the one resulting from AEP cleavage, but followed by 18 
extra amino acids, which dramatically reduces its ability to 
aggregate.
Strikingly, the resulting Tau truncated isoform is reduced 
in Alzheimer’s disease patients’ brain, especially in later 
stages of the disease, in contrast to increasing total Tau lev-
els. Despite the similarity of its sequence to that of the AEP 
truncated isoform, this new Tau isoform is able to bind to 
microtubules and is less prone to aggregate, suggesting a 
beneficial role in the pathology.
Materials and methods
Human brain samples
Hippocampal and frontal lateral cortex brain samples from 
sporadic Alzheimer’s disease patients and control subjects 
were kindly provided by Dr. A. Rabano from Banco de Teji-
dos (Fundación CIEN, Instituto de Salud Carlos III, Madrid, 
Spain). Based on quantitative pathological features, the Alz-
heimer’s brain specimens were classified according to Braak 
stages I (n = 3), II (n = 6), III (n = 4), IV (n = 1), V (n = 10) 
and VI (n = 8), and non-demented control subjects (n = 10) 
(see Supplementary table 1, online resource for further sub-
ject information). Written informed consent premortem was 
obtained from all patients.
Nomenclature
Classical nomenclature [2] for MAPT gene exon/intron 
numbers has been used consistently throughout the paper, 
although some of the databases (such as ENSEMBL: https:// 
www. ensem bl. org/ index. html) employ a different nomen-
clature assigning different numbers to exons and introns 
(according to ENSEMBL, intron retention would take place 
in intron 13).
As for the new Tau isoform described in this work, the 
transcript including the translation of intron 12 up to the first 
stop codon has been named TIR-MAPT (Truncated by Intron 
Retention MAPT), while the protein generated from such 
transcript has been termed W-Tau, due to the appearance of 
two characteristic tryptophan residues (W) in this isoform, 
an amino acid that does not appear elsewhere within the 
Tau molecule.
In addition, Tau truncated by asparagine endopeptidase, 
as previously described by Zhang et al. [63] is referred to as 
ET-Tau (Endopeptidase Truncated Tau) throughout the text.
Cell culture
HEK293T (CRL-11268, ATCC), SK-N-MC (HTB-10, 
ATCC), and SH-SY5Y (CRL-2266, ATCC) cells were 
cultured in DMEM or MEM supplemented with 10% fetal 
bovine serum, 2 mM glutamine, non-essential amino acids, 
10 U/ml penicillin and 10 µg/ml streptomycin, at 37 °C and 
5%  CO2.
TIR‑MAPT and ET‑MAPT cloning
TIR-MAPT transcript was obtained from an SH-SH5Y RNA 
extract, using specific oligos (TauNt and TauD, see Sup-
plementary table 2, online resource) and was cloned into 
pBlueScript-SK + (212,205, Agilent Technologies), thanks 
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to a TA-cloning strategy [37]. Using specific oligos that 
include the appropriate restriction sites (A1 and TIR-T-
BglII and ET-T-BglII, see Supplementary table 2, online 
resource) TIR-MAPT and ET-MAPT were subcloned into 
a eukaryotic expression vector pSG5 (216201, Agilent 
technologies). Similarly, Tau isoforms were cloned into a 
prokaryotic expression vector pRK172 using specific oligos 
(TAU-PRK172 fw, TIR-T-pRKpWPI rv and ET-T-pRKpWPI 
rv; see Supplementary table 2, online resource). After clon-
ing, all vectors were sequenced using the described oligos 
(Supplementary table 2, online resource).
RNA‑seq data analysis
RNA-seq raw data from 363 samples of 3 brain regions 
(frontal cortex, dorsolateral prefrontal cortex and hippocam-
pus) of 180 human brain healthy donors were retrieved from 
the Genotype-Tissue Expression (GTEx) project [36] (Sup-
plementary table 3, online resource). SRA files were con-
verted to FASTQ files and reads were re-mapped to human 
genome GRCh38 using STAR version 2.5.2a [18]. Gene 
expression quantification was performed with RSEM ver-
sion 1.3.1 [35].
The annotation file was retrieved from GENCODE (gen-
code.v23.annotation.gtf) and was modified to include a new 
MAPT-related gene (TIR-MAPT) whose genome coordinates 
are chr17:45894382–46018851, which includes part of the 
intron 12 (chr17:46018731–46018851) as the 3′ end of the 
gene in the region mapping the oligonucleotide sequence 
TauD (Supplementary Table 2, online resource and Fig. 1). 
Gene expression levels were obtained from RSEM as tran-
scripts per kilobase million (TPM) values. Expression lev-
els of MAPT and TIR-MAPT genes were analyzed per brain 
region. For those donors with more than one sample in the 
same brain region, analysis was done only in the sample with 
highest MAPT expression.
Bacteria culture and Tau purification
Upon cloning, pRK172 vectors encoding different Tau iso-
forms were transformed in BL21 E. coli competent cells by 
electroporation, from which Tau was purified, as described 
elsewhere [49]. These bacteria were cultured in LB medium 
with 100 ng/ml of ampicillin at 37 °C overnight. Bacterial 
suspensions were transferred to 1L of LB with 100 ng/ml of 
ampicillin and further incubated at 37 °C, up until optical 
density readings at 600 nm ranged between 0.6 and 0.8. At 
this point, 0.4 mM of IPTG was added to each sample so as 
to trigger transcription, and incubated once again at 37 °C 
for 2 h. The samples were centrifuged at 2950×g at 4 °C for 
20 min and pellets were resuspended in Tau buffer, which 
consists of buffer A (0.1 M MES pH 6.4, 0.5 mM  MgCl2 and 
2 mM EGT) supplemented with 1 mM PMSF; 0.5 NaCl and 
5 mM β-mercaptoethanol. Resuspended pellets were soni-
cated on ice at 24 microns peak to peak (mpp) five times for 
1 min, waiting 10 s between repetitions. Upon sonication, 
samples were centrifuged at 13,850×g at 4° C for 10 min 
and the resultant supernatants were subjected to 5 min at 
100° C and 5 min on ice before centrifuging one more time 
at 13,850×g at 4 °C for 30 min. Supernatants were kept and 
Tris 1 M was added until pH reaches a level of 11, to get rid 
of residual DNA. Ammonium sulfate 50% was added to the 
samples and they were incubated agitating at 4 °C for at least 
1 h before centrifuging again at 13,850×g at 4 °C for 1 h. 
Pellets containing purified Tau were resuspended in buffer 
A and the purification process was checked by SDS-PAGE 
and Coomassie blue staining to check if any other protein 
bands appeared upon Coomassie blue staining.
Tau protein quantitation
Protein concentration for each Tau isoform was first deter-
mined by means of absorbance measurements corrected by 
individually calculated extinction coefficients (ε), based on 
the specific amino acid sequence of each isoform [24] (Sup-
plementary Table 4, online resource). Namely, we measured 
Tau concentration as indicated by Kundel and collabora-
tors [34]: absorbance at 280 nm (A280) was measured for 
each Tau isoform and concentration was determined as the 
ratio between A280 and ε. Extinction coefficients can be esti-
mated from the amino acid sequence of the protein [24], 
according to the equation: ε280 = number of tryptophan 
residues (W) × 5500 + tyrosine residues × 1490 [17]. Using 
this equation and the amino acid composition of each Tau 
isoform, the extinction coefficients were calculated for each 
one (Supplementary Table 4, online resource). Calculated 
values for T42 and T30 coincide with those calculated by 
Kundel [34], which has been typically used for all CNS 
human Tau isoforms [21], but are not valid for W-Tau iso-
forms that contain 2 extra tryptophan residues nor for ET-
Tau isoforms, which lack 1 tyrosine that appear on the rest of 
the isoforms. Coomassie blue staining of samples containing 
the same amount of protein was performed to confirm their 
concentrations.
RNA extraction and purification
Either total RNA or cytosolic enriched fraction RNA was 
purified from cells using RNAeasy Mini Kit (74104, Qiagen) 
following the protocols described in Qiagen handbook. For 
brain tissue, previous homogenization using a TissueLyser 
(Retsch MM300, Qiagen, Hilden, Germany) (30 Hz, 5 min) 
with 5-mm stainless steel beads (69989, Qiagen) in 700 µl 
QIAzol Lysis Reagent (79306, Qiagen) was performed. RNA 
integrity numbers (RIN) were calculated using the Agilent 
162 Acta Neuropathologica (2021) 142:159–177
1 3
2100 Bioanalyzer system (Agilent Technologies), and only 
RNAs with RIN > 5 were used for RT-qPCR.
RNA was purified using RNAeasy Mini Kit (74104, Qia-
gen) with the following modifications. Cells were pelleted 
and frozen at -80 °C. Pellets were carefully resuspended in 
175 μl of precooled (4 °C) buffer: 50 mM TrisHCl pH 8, 
140 mM NaCl, 1.5 mM  MgCl2, 0.5% (v/v) Nonidet P40 
(1.06 g/ml) plus 1 mM DTT just before use and incubated 
on ice for 5 min. Lysates were centrifuged at 4 °C for 2 min 
at 300 × g. Supernatants were kept as cytoplasmic-enriched 
fraction. To each fraction, 600 μl of Buffer RLT were added. 
After vortexing, 430 μl of ethanol 100% were added to the 
homogenized lysate. Samples were transferred to RNeasy 
spin columns, centrifuged for 15 s at 9000×g and the flow-
through was discarded. Samples were treated with 10 µl 
of DNase in 70 µl of buffer RDD (RNase-free DNase Set 
79254, Qiagen) for 15 min at room temperature. The rest 
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of the extraction was performed following the protocol and 
RNA was collected in 30 µl of RNAse free water twice.
Semi‑quantitative PCR
Total RNA was purified using RNAeasy Mini Kit (74104, 
Qiagen) following provider’s guidelines. Cytoplasmic 
RNA fractions were purified as previously described. 
Retrotranscription was performed using 40 ng/µl of RNA 
with the Transcriptor First Strand cDNA Synthesis Kit 
(04379012001, Roche) using oligo(dT)18 primer. Semi-
quantitative PCR was performed using 1 µl of cDNA (0.5 ng/
µl) supplemented with 2.5 mM  MgCl2, 0.2 mM each dNTP, 
1.3 M betaine, 0.5 mM of each primer (described in supple-
mentary table 2, online resource) and 0.025 U/ml of  GoTaq® 
Flexi DNA Polymerase (M829, Promega), in the following 
conditions: 95 °C for 2 min, and 35 cycles (PCR1-8) or 30 
cycles (PCR9-13) of 95 °C for 45 s, 58.6 °C for 45 s and 
72 °C for 45 s, followed by a final extension of 10 min at 
72 °C. PCR combinations are described in supplementary 
table 5, online resource.
Detection of Tau levels by quantitative RT‑PCR
RNA was retrotranscribed with the Transcriptor First Strand 
cDNA Synthesis Kit (04379012001, Roche) using 20 ng/
µl RNA with oligo(dT)18 primer. Quantitative PCR was 
performed in a LightCycler480 (Roche) in the following 
conditions: 50 °C for 2 min, 95 °C for 10 min, and 40 cycles 
of 95 °C for 15 s and 60 °C for 1 min. Specific intron-span-
ning oligonucleotides against MAPT or TIR-MAPT transcript 
were designed (MAPT-E11-E13-fw/rv and TIR-T-fw/rv, 
respectively; see Supplementary table 2, online resource). 
Gene expression was normalized to GAPDH expression 
using TaqMan primer human GAPDH (Hs02758991_g1, 
Applied Biosystems). For every RT-qPCR experiment, only 
samples with RIN above 5 were used.
Detection of Tau levels by Western blot
Frozen brain tissue was homogenized using a TissueLyser 
(Retsch MM300, Qiagen, Hilden, Germany) (30 Hz, 5 min) 
with 5-mm stainless steel beads (69,989, Qiagen) in total 
extraction buffer: 50 mM Tris–HCl pH 7.5, 300 mM NaCl, 
0.5% SDS (sodium dodecyl sulphate) and 1% Triton X-100 
(Fig. 2d, e and Supplementary Fig. 6b, online resource). 
The same buffer was also used for cells (Figs. 2b, c, 3b, 4a, 
5b and Supplementary Fig. 4b, online resource and Sup-
plementary Fig. 5a, b, online resource). For human cortex 
brain extracts, a strong lysis buffer (50 mM Tris–HCl pH 
7.6, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% SDS) 
was also used in Fig. 7b. The homogenates are incubated 
for 15 min at 95 °C, centrifuged (16,100×g, 10 min) and 
the supernatant was considered the brain extract. Protein 
concentration was measured using the DC protein assay 
kit (500-0111, Bio-Rad). From each sample, equal amount 
of total protein was resolved on a 10% Bis–Tris gel and 
transferred to nitrocellulose membranes. Blots are probed 
with the corresponding primary antibodies (see below), fol-
lowed by horseradish peroxidase-conjugated anti-mouse or 
anti-rabbit antibody (Dako, Glostrup, Denmark). Protein 
expression was quantified by measuring the ECL signal with 
ImageJ software (Fig. 7 and Supplementary Fig. 6, online 
resource) (http:// rsbweb. nih. gov/ ij/) or with Quantity  One® 
1-D analysis software from Bio-Rad.
Antibodies
Different antibodies were used for the different essays, 
as indicated in each one. Altogether, Tau 12 (Millipore, 
MAB2241; amino acids 6-18, diluted 1/1000), Tau 5 (Calbi-
ochem, D00139295, amino acids 210-241, diluted 1/1000), 
Tau antibody (NOVUSBIO, NB100-82247, epitope around 
amino acid 231, diluted 1/500) and Tau 7.51 ([44], amino 
acids 315-376, diluted 1/100) were used as antibodies rec-
ognizing all Tau isoforms; Tau 1 (Chemicon, MAB3420, 
diluted 1/1000) recognizing dephosphorylated residues 
Ser195, 198, 199 and 202 and AT8 (phospho-Ser202/
Thr205; Innogenetics, MN1020, diluted 1/100), AT180 
(phospho-Thr231; Innogenetics, MN1040, diluted 1/100), 
Tau 404 (phospho-Ser404; Life Technologies, 44758G, 
Fig. 1  TIR-MAPT RNA expression. a Schematic representation of the 
MAPT gene and MAPT and TIR-MAPT mRNAs generated from it. A, 
C, D and E represent the hybridization sites of the primers designed 
for semi-quantitative PCR employed for the PCRs in b (Supplemen-
tary Table 2, online resource). The fragment of intron 12 that would 
remain upon retention is represented with colored stripes. b Repre-
sentative images of agarose gels showing of semi-quantitative PCR 
results using total or cytoplasmic-enriched RNA of SH-SY5Y cells. 
Results showed the existence of RNA species from exon 11 to intron 
12 where intron 11 was spliced out (PCR 5 and 6). Controls of the 
addition (RT+) or no addition of retrotranscriptase (RT−) were 
included. PCR 9 shows MAPT in which both intron 11 and 12 are 
spliced out. Detailed information of all semi-quantitative PCR com-
binations and amplicon sizes is provided in Supplementary Table 5, 
online resource. c Schematic representation of the MAPT gene 
including the hybridization sites of the oligos used for quantitative 
PCR. d TIR-MAPT RNA levels by qPCR in cytoplasmic-enriched 
fraction or whole extracts (total) of SH-SY5Y cells. e Comparison of 
TIR-MAPT level in SH-SY5Y cells and hippocampus and frontal lat-
eral cortex of human brain. Graphs show means and SE of technical 
triplicates. f Percentage of brain samples having expression of MAPT 
or TIR-MAPT genes. Data are shown for three different regions within 
brains (see Supplementary Table  3, online resource). g Scatter dot 
blot of expression values of MAPT and TIR-MAPT genes in brain 
regions having TPM (transcripts per kilobase million) > 0. Number 
of samples f, g: cortex = 122; frontal cortex = 113; hippocampus = 98. 
Graphs represent mean and SEM. p values were calculated using a T 
test, ****p value ≤ 0.0001
◂
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diluted 1/1000), Tau 396 (phospho-Ser396; Life Technolo-
gies, 44752G, diluted 1/1000) and PHF1 (phospho-Ser396/
Ser404, kind gift of Peter Davies [26], diluted 1/100) as anti-
bodies recognizing phosphorylated Tau isoforms. In addi-
tion, β-actin (SIGMA A5441, diluted 1/20000) or GAPDH 
(Cell signalling, 2118, diluted 1/1000 antibodies were used 
as loading control.
A peptide composed of the W-Tau unique sequence 
(KKVKGVGWVGCCPWVYGH) (W-Tau peptide) was 
synthesised and a polyclonal IgG antibody against that 
peptide was obtained from Abyntek (Bizkaia, Spain), 
using New Zealand rabbit as host strain. This antibody 
was named W-Tau antibody and its specificity was tested 
(diluted 1/1000) to ensure it reacts exclusively with TIR-
Tau but not with other Tau isoforms (Fig. 2a–c).
Fig. 2  W-Tau antibody valida-
tion and protein expression in 
human brain. a Immunopre-
cipitation assay of HEK239T 
cells overexpressing W-T30 
using W-Tau (Abyntek) or 
total Tau (NOVUSBIO, 
NB100-82247) antibodies 
and Western blot detection of 
immunoprecipitated Tau using 
7.51 antibody. b Immunopre-
cipitation of the same cells 
overexpressing W-T30 and 
control untransfected cells using 
W-Tau antibody and detec-
tion of immunoprecipitated 
Tau using total Tau (Tau 7.51) 
antibody. c HEK293T cells 
were transfected with eukary-
otic expression vectors empty 
or encoding different MAPT 
isoforms (T42, T30, W-T42, 
W-T30, ET-42 and ET-T30). 
Representative Western Blot for 
Tau 7.51 and W-Tau antibodies 
proving W-Tau specificity. d 
Western blot detection of W-Tau 
in frontal lateral cortex and hip-
pocampus of one human subject 
that show bands at 50 kDa 
(W-T42), 38 KDa (W-T30), and 
31 KDa (W-Tau truncated). e 
Representative Western blot of 
frontal lateral cortex and hip-
pocampus samples of the same 
three human subjects (a, b, c) 
showing the presence of W-Tau 
and total Tau (Tau5)
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Immunoprecipitation was performed with W-Tau and 
total Tau (NOVUSBIO, NB100-82247) antibodies using 
SantaCruz Immunoprecipitation Kit (SC-2003) using 
500 µg of whole cell extracts and following provider’s 
guidelines.
Tau phosphorylation determination
HEK293T cells were transfected with pSG5 plasmids (2 µg/
p60) encoding different Tau isoforms using Lipofectamine 
and Plus reagents following instructions of the supplier 
(#18324 and #11514, respectively, Life Technologies). 
48 h after transfection, cells were collected, pelleted and 
homogenized in 200 µl of total extraction buffer. Protein 
concentrations were measured using the DC protein assay 
kit (500-0111, Bio-Rad) and samples containing equivalent 
amounts of protein were analyzed by Western blot, as previ-
ously described, using nitrocellulose membranes. Immuno-
detection was performed with antibodies Tau 7.51 and Tau 
5 for total Tau, Tau 1 for dephosphorylated Tau and AT8, 
AT180, Tau 404, Tau 396 and PHF1 for phosphorylated Tau.
Tau solubility determination
Once again, HEK293T cells were transfected with pSG5 
plasmids (2 µg/p60) encoding different Tau isoforms using 
Lipofectamine and Plus reagents (Life Technologies). After 
48 h, cells were collected, pelleted and homogenized in 
150 µl of lysis buffer (50 mM Tris–HCl (pH 7,4), 150 mM 
NaCl, 20 mM NaF, 1 mM  Na3VO4, 0.5 mM  MgSO4; sup-
plemented with protease inhibitors cocktail, 04693159001 
Roche) at 4 °C. Homogenates were centrifuged at 27,000×g 
for 20 min at 4 °C. Pellets were discarded and 1% sarkosyl 
was added to the supernatants, being incubated for 1.5 h agi-
tating at room temperature. Upon incubation, samples were 
centrifuged at 150,000×g during 45 min at 4 °C. Superna-
tants were kept as sarkosyl-soluble fraction and pellets were 
resuspended in 100 µl of a mix of total extraction buffer 
and loading buffer (1:1) and considered sarkosyl-insoluble 
fraction.
Results were further confirmed by carrying out a similar 
protocol to measure Triton X-100 solubility. Namely, pel-
leted cells were homogenized in 500 µl of lysis buffer (1% 
Triton X-100, 50 mM Tris–HCl pH 7, 100 mM NaCl and 
1 mM EDTA) and incubated 20 min at 4 °C. The samples 
were centrifuged at 18,000×g for 5 min and the supernatants 
were kept as soluble fraction. Pellets were resuspended in 
total extraction buffer (see point 11 of methods) and consid-
ered Triton-insoluble fraction.
In both cases, equivalent volumes of each sample were 
then analyzed by Westernblotting.
Tau in vitro aggregation determination
Tau aggregates were grown for the different Tau isoforms by 
vapor diffusion in hanging drops in the standard way used for 
protein crystallizations [15]. The different Tau isoforms were 
purified from bacteria as described above and their concen-
tration was estimated by measuring absorbance at 280 nm 
and taking into account individually calculated extinction 
coefficients for each isoform (Supplementary table 4, online 
resource) and confirmed by means of Coomassie Blue stain-
ing. Equivalent quantities of each isoform were added to 
the corresponding volume of buffer A (0.1 M MES pH 6.4, 
0.5 mM  MgCl2 and 2 mM EGT) plus 50 mM NaCl in the 
presence of heparin, reaching a concentration of 1 mg/ml. 
The reservoir contained 0.2 M NaCl in buffer A. Aggregates 
were obtained after incubation for 10 days at room tempera-
ture (see also [49]). An aliquot was kept for electron micros-
copy analysis, and the rest of the samples were centrifuged 
in Airfuga at 28 lb per square inch (psi) for 30 min at room 
temperature to separate soluble and aggregated protein. The 
fractionated proteins were characterized by electrophoresis 
and Western blot.
Tau microtubule‑binding capacity assay
For microtubule preparation, the brains of 12 2-month-old 
C57BL/6J mice were homogenized with a potter in iso-
tonic buffer (0.32 M sucrose, 1 mM EGTA, 1 mM  MgCl2, 
10 mM phosphate buffer pH 7 and 1 mM PMSF) at 4 °C. 
Supernatant was collected after 40 min ultracentrifugation 
at 100,000×g at 4 °C in an Optima L-100 XP Ultracentri-
fuge (Beckman Coulter). 100 μl of this supernatant were 
incubated with equal quantity of protein for the different 
Tau isoforms, purified from bacteria as mentioned above 
during 30 min at 37 °C, in the presence of 30% glycerol, 
1 mM PMSF and 1 mM GTP to promote tubulin polymeri-
zation. After that, samples were ultracentrifuged for 60 min 
at 100,000×g at 25 °C.
Equivalent volumes of pellets containing microtubules 
and microtubule-bound Tau were analyzed by Western Blot, 
using Tau 5 and tubulin antibodies and the ratio between Tau 
5 and tubulin signal was calculated for each isoform as their 
microtubule-binding ratio, normalized to the corresponding 
full-length isoform.
GSK3 modulation
SK-N-MC human neuroblastoma cells (ATCC ® HTB-10™) 
were treated with GSK3 inhibitors SB216763 (25  µM, 
GlaxoSmithKline compounds [13]) and AR-14418 (10 µM, 
AstraZeneca compound [7]) or Aβ1–42 (1.1 µM; Neosystem 
Laboratoire, Strasbourg, France) for 24 h and whole cell 
extracts were used for Western blot analysis, probing the 
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blots with W-Tau antibody. From those cells treated with 
AR-14418 and Aβ1-42, RNA-enriched cytoplasmic fraction 
was also retrieved and TIR-MAPT RNA levels were assessed 
by quantitative RT-PCR as previously described.
Splicing factor binding site prediction analysis
Exonic and intronic human MAPT sequences were 
retr ieved from ENSEMBL (ENSG00000186868). 
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Exon 12–exon 13 and exon 12–intron 12 sequences 
(Exon 13–exon 14 and exon 13–intron 13, according to 
ENSEMBL nomenclature of Tau exons/introns) were 
analyzed using ESEFinder 3.0 (http:// exon. cshl. edu/ 
ESE/) [53]. ESEFinder settings were adjusted to show 
binding sites with score 4.0 or higher. The analysis was 
completed by a detailed bibliographic search comparing 
SRSF2 binding sites described in Masaki et al., 2019 and 
Cavaloc et al., 1999 [11, 38] with junctions MAPT Exon 
12–exon 13 and exon 12–intron 12 sequences.
Statistical analysis
Quantitative data, represented as mean ± SD or SEM, were 
compared between groups using the two-tailed Student’s 
t test. For multiple comparisons, one-way ANOVA and 
Dunnett’s test were performed to compare each isoform 
and the correspondent full-length isoform. When the dis-
tribution of the data was not Gaussian a nonparametric 
Kruskal–Wallis test was used. The differences are given 
with their corresponding statistical significance or p value, 
which is the probability that the difference occurred merely 
by chance under the null hypothesis (*p ≤ 0.05; **p ≤ 0.01; 
***p ≤ 0.001; ****p ≤ 0.0001; N.S. not significant). The 
method used for each experiment is specified in the cor-
responding figure legend.
Results
New alternative splicing variant of MAPT present 
in mature human transcriptome
Recently, the presence of new protein isoforms generated by 
intron retention in neurodegenerative diseases such as Alz-
heimer’s disease [45] and Huntington’s disease [52] has been 
described. This, together with evidence of an asparagine-
endopeptidase-truncated Tau isoform [63], whose cleavage 
point coincides with the end of exon 12 led us to seek pos-
sible intron retention events within the intron between exons 
12 and 13 (intron 12). Curiously, human intron 12 includes 
a canonical stop codon sequence followed by a polyadenyla-
tion canonical site, so intron 12-containing species would 
be translated as a truncated protein similar to the truncated 
isoform mediated by AEP (ET-Tau), with 18 more amino 
acids, which we have named W-Tau (Fig. 1a). Importantly, 
this isoform would be human-specific, since this polyade-
nylation site cannot be found in other species, such as mice.
We could detect intron 12 retaining RNA species in which 
intron 11 was spliced out in SH-SY5Y mature (polyA posi-
tive) total RNA and cytoplasmic-enriched fraction (Fig. 1b, 
Supplementary Fig. 1 and Supplementary Tables 2 and 5, 
online resources). This was observed by means of semi-
quantitative PCR using an exon 11-matching forward oligo 
and intron 12 reverse oligos (Fig. 1a, b, Supplementary 
Table 5, online resource, PCR 5 and 6). As expected, we 
could also detect the equivalent amplicon using an exon 
12-matching reverse oligo in which intron 12 was spliced out 
(Fig. 1a, b, Supplementary Table 5, online resource, PCR 
9). Additionally, we could observe similar results using an 
exon 12 forward oligo and intron 12 reverse oligos (Sup-
plementary Fig. 1a, b, Supplementary Table 5 PCR 1 and 2, 
online resources). Genomic DNA contamination was ruled 
out using intron-spanning forward oligos (Supplementary 
Fig. 1a, b and Supplementary Table 5, PCR 3, 4, 7 and 
8; online resources). Curiously, intron-spanning primers 
matching exon 10 to detect RNA species containing intron 
12 never detected these as mature cytoplasmic polyA posi-
tive RNA (Supplementary Fig. 1a, b and Supplementary 
Table 5, PCR 7 and 8; online resources). Exon 10 is spliced 
out in Tau isoforms with three repeats (Tau 3R) and it has 
been previously described that proliferative SH-SY5Y cells 
mainly express these Tau isoforms [57], so detection of RNA 
species with partial inclusion of exon 10 was not expected 
a priori. As a control, mature polyA positive RNA species 
including only exons were found in our samples (Supple-
mentary Fig. 1a, b and Supplementary Table 5, PCR 10–12; 
online resources), even detecting transcripts that include 
exon 10 (Tau 4R), although with decreased efficiency (Sup-
plementary Fig. 1a, b and Supplementary table 5, PCR 
Fig. 3  W-Tau phosphorylation pattern. a Schematic representation of 
different Tau protein isoforms: full-length isoform with four repeats 
(R) and two insertions (N) (T42), full-length isoform with three 
repeats and no insertions (T30), the truncated by intron retention iso-
forms W-Tau with four repeats, two insertions and an extra peptide 
(W-T42) or with three repeats, no insertions and the extra peptide 
(W-T30); and the correspondent asparagine-endopeptidase-truncated 
isoforms (ET-T42 and ET-T30). Representation of the antibodies rec-
ognizing the Tau molecule at their corresponding epitopes: Antibod-
ies recognize all isoforms of Tau (Tau12 on amino acids 6–18; Tau 5 
on amino acids 210–241 and Tau 7.51 on amino acids 315–376) or 
specific against dephosphorylated Tau in residues Ser195, 198, 199 
and 202 (Tau1), and phospho-Tau in residues Ser202/Thr205 (AT8), 
Thr231 (AT180), Ser404 (Tau404), Ser396 (Tau396) and Ser396/
Ser404 (PHF1). W-Tau antibody recognizes the unique peptide pre-
sent on W-Tau isoforms. b Samples from HEK293T cells transfected 
with the different isoforms were probed with different antibodies for 
phosphorylated and non-phosphorylated Tau. c Quantification of 
the data of different Tau epitopes with respect to total Tau measured 
with Tau 7.51 antibody, showing mean and SEM (n = 4). One-way 
ANOVA for multiple comparisons followed by a Kruskal–Wallis test 
was performed to compare each isoform and T42 full-length level of 
phosphorylation
◂
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12; online resources). These results were also validated by 
qPCR using the same oligos (Supplementary Fig. 1c, online 
resource) and different, qPCR-optimized ones (Fig. 1c, d, 
Supplementary Table 2, online resource). Moreover, we 
were able to amplify whole-length TIR-MAPT cDNA from 
starting codon to intron 12 using specific primers (TauNt and 
TauD, Supplementary Table 2, online resource) in SH-SY5Y 
cells. This cDNA would correspond to TIR-MAPT with three 
repeats and no inserts (TIR-T30).
More importantly, TIR-MAPT polyA positive mRNA 
was found in both hippocampus and frontal cortex in human 
samples (Fig. 1e). Remarkably, TIR-MAPT expression lev-
els in human brain were more than 100-fold the expression 
found in SH-SY5Y, suggesting a higher relevance of this 
RNA species in human brains than in cultured cells.
Fig. 4  W-Tau aggregation 
capacity. a Representative 
Western blot of the presence 
of Tau in 1% sarkosyl-soluble 
and insoluble cell fractions of 
HEK293T cell overexpressing 
different Tau isoforms (T42, 
T30, W-T42, W-T30, ET-42 
and ET-T30) detected with Tau 
5 antibody. b, c Quantification 
of the signal obtained from Tau 
5 showing sarkosyl-soluble 
vs insoluble fractions (b) or 
soluble/insoluble ratio (c). 
Graphs show means and SEM 
(N = 3). One-way ANOVA for 
multiple comparisons followed 
by a Kruskal–Wallis test was 
performed to compare each 
isoform with the correspondent 
full-length isoform, *p ≤ 0.05. d 
Representative electron micros-
copy images of Tau aggregates 
obtained upon in vitro incuba-
tion from partially purified T42, 
W-T42, and ET-42 extracts 
from bacteria in the presence of 
heparin to prompt aggregates 
formation. Scale bars show 
500 nm wide. e Western blot 
showing soluble (supernatant) 
and aggregated (pellet) protein 
from the incubation in d, upon 
centrifugation to separate both 
fractions. Quantification shows 
the ratio between soluble and 
aggregated protein
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Fig. 5  Modulation of TIR-MAPT and W-Tau by GSK3. a. Detection 
of mature cytoplasmic RNA levels of TIR-MAPT, total MAPT and 
the ratio TIR-MAPT/total MAPT in SK-N-MC human neuroblas-
toma cell line in the absence or presence of 5  µg/ml amyloid-β1–42 
and the GSK3 inhibitor AR-014418 (10 µM) for 24 h. Graphs show 
mean and SEM. One-way ANOVA and Dunnett’s multiple com-
parisons test were performed and statistical significance between 
untreated and cells treated with either Aβ1–42 and AR-014418 was 
given. ***p ≤ 0.001; ****p ≤ 0.0001. b Western blot analysis of the 
protein levels of W-Tau (W-Tau antibody) in SK-N-MC cells treated 
with SB216763 (25  µM), Aβ1–42 (1.1  µM) or AR-14418 (10  µM). 
Right panel shows the quantification of the signal of complete lanes 
obtained with W-Tau antibody. Graphs show mean and SEM. One-
way ANOVA for multiple comparisons followed by a Kruskal–Wallis 
test was performed to compare treated and untreated cells. *p ≤ 0.05. 
c Schematic representation of the modulation of TIR-MAPT by splic-
ing factor SC35, regulated by GSK3-mediated phosphorylation. Blue 
arrows represent activation; red, truncated arrows represent inhibition
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Additionally, RNA-seq data from 363 samples from 3 
different brain regions of 180 healthy donors were used to 
confirm the existence of TIR-MAPT transcripts (Supple-
mentary Table 3, online resource). TIR-MAPT gene mature 
mRNA containing the first part of intron 12 up until the 
canonical stop site was expressed in the majority of samples 
(Fig. 1f) supporting our previous findings in a big cohort of 
human samples. Gene expression of MAPT mature mRNA 
was compared with TIR-MAPT (Fig. 1g). Even though TIR-
MAPT is expressed at lower levels, the great number of 
samples expressing this intron-retaining species suggests a 
relevant function in human brain. Among the RNA species 
containing intron 12, some of the reads would correspond 
to a putative Tau protein without inserts, and with 3 tan-
dem repeats (T30), but substituting the 3′-terminal of the 
RNA for the sequence of intron 12 until the first stop codon; 
what we have named TIR-T30. The putative translation of 
this RNA species into a protein has been named W-T30, 
due to the presence of two tryptophan residues (W) in the 
sequence of intron 12 translation (Supplementary Fig. 2, 
online resource). This RNA species would be equivalent to 
that found in SH-SY5Y cells.
W‑Tau expression in human brain
With the aim of determining whether this new Tau isoform 
is present in human brain as a protein, we obtained a spe-
cific antibody against the unique 18 amino acid sequence 
of W-Tau peptide (KKVKGVGWVGCCPWVYGH; W-Tau 
antibody), corresponding to the translation of intron 12 until 
the canonical stop codon. To confirm the specificity of this 
antibody, we cloned TIR-MAPT cDNA obtained from SH-
SY5Y (TIR-T30, which would correspond to W-T30 as a 
protein) into the expression vector pSG5 (216201, Agilent 
technologies) and used it to overexpress this isoform in 
HEK293T cells. We demonstrated that W-T30 could be spe-
cifically immunoprecipitated with both W-Tau (Abyntek) or 
Total Tau (NOVUSBIO, NB100-82247) antibodies (Fig. 2a) 
and then that W-Tau antibody only precipitates W-Tau with-
out any background on control untreated cells (Fig. 2b). In 
both cases, the immunoprecipitated protein was confirmed 
to be Tau by detecting it by Western blot with Tau 7.51 
antibody.
To confirm this specificity and contrast it with other Tau 
isoforms, we further modified the eukaryotic vector pSG5 to 
include exon 10 corresponding to the fourth tandem repeat 
of the microtubule-binding domain and the two Tau inserts 
(thus obtaining W-T42). Additionally, asparagine-endopepti-
dase-truncated Tau corresponding isoforms were also cloned 
into pSG5 expression vector (ET: Endopeptidase truncated; 
ET-T42 and ET-T30); mimicking the cut of endopeptidase by 
including a stop codon after the one that encodes asparagine 
368. We used this vector encoding W-Tau, ET-Tau and the 
full-length equivalents (T42 and T30) to overexpress these 
proteins on HEK293T cells, together with control cells trans-
fected with the empty pSG5 vector. We observed that, while 
total Tau antibodies (such as Tau 7.51) recognize all these 
isoforms, W-Tau antibody only shows signal for W-Tau iso-
forms, without any background on other species (Fig. 2c).
Once the specificity of the antibody was confirmed, we 
probed human hippocampal and frontal lateral cortex sam-
ples with it, confirming the existence of this novel Tau iso-
form as a protein in human brain (Fig. 2d, e). In the first 
image, we show an example of a human subject that exhibits 
a predominant band close to 52 KDa that may correspond to 
a 4R form of W-Tau (Fig. 2d, 50 kDa band). Also, a smaller 
band at 38 KDa suggest the presence of W-T30 isoform in 
the hippocampal sample. Moreover, there is another band 
around 31 KDa that is recognized by W-Tau antibody, that 
might be explained as a proteolytic cleavage of the above 
bands, although further studies will be necessary to unravel 
the identity of this band. Then, we studied W-Tau expression 
in another three human subjects by comparing hippocam-
pal and frontal lateral cortex samples (Fig. 2e). We could 
observe a predominant expression of 52 KDa 4R W-Tau 
bands, especially in frontal lateral cortex whose levels vary 
among individuals, and the 31 KDa band that may corre-
spond to the truncated W-Tau form. All these results together 
indicate that intron 12 retaining Tau isoforms are expressed 
in human brain, of which two of them show similar molec-
ular weights to those of W-T42 and W-T30 in cells upon 
overexpression.
W‑Tau phosphorylation
The pSG5 vectors encoding the different isoforms were 
employed to induce overexpression of these isoforms, to test 
W-Tau properties and compare them to those of full-length 
isoforms (T42 and T30) and those of asparagine-endopepti-
dase-truncated isoforms (ET-42 and ET30) (Fig. 3a). First, 
we studied the phosphorylation of W-Tau isoform, compar-
ing it with the phosphorylation found in other Tau isoforms, 
expressed in HEK293T cells. We expected differential detec-
tions according to the epitopes that remain despite trunca-
tion and those that are lost because of it (Fig. 3a). Indeed, 
phosphorylation of AT8 sites Ser202/Thr205 and AT180 
(phospho-Thr231) still occurred in truncated isoforms 
(Fig. 3b, c). However, as expected, PHF1 phosphorylation 
sites Ser396/Ser404 were not observed in truncated isoforms 
because these sequences are not present in those species. 
Also, some of the modifiable residues remained in dephos-
phorylated state, as shown by Tau 1 antibody label (dephos-
pho- Ser195, 198, 199 and 202) (Fig. 3b, c) and negative 
staining for phospho-Thr212 and phospho-Ser214 (AT100) 
(data not shown).
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These results point out a similar post-translational pro-
cessing of W-Tau when compared to other Tau isoforms, 
at least regarding its phosphorylation on the mentioned 
epitopes.
W‑Tau microtubule stabilization and binding 
capacity
Then, we analyzed the effect of W-Tau on the polymerization 
of mouse brain microtubules in vitro by means of electron 
microscopy in the presence or absence of W-Tau, showing a 
higher proportion of microtubules in the presence of W-Tau 
(W-T42) (Supplementary Fig. 3a, online resource).
In addition, we analyzed the capacity of T42, W-T42, and 
ET-T42 purified from Tau-expressing bacteria (Supplemen-
tary Fig. 3b, online resource) to bind to microtubules puri-
fied from mouse brain, separating microtubule-bound and 
free Tau by centrifugation and characterizing Tau enrich-
ment with respect to tubulin in microtubule-bound fraction 
by Western blot with Tau 5 antibody. As expected, all the 
tested isoforms were able to bind to microtubules (Supple-
mentary Fig. 3b, c, online resource), since all of them con-
tain microtubule-binding repeats. Of note, W-T42 showed 
a high affinity to bind microtubules compared to other iso-
forms harboring four repeats and two inserts (Supplemen-
tary Fig. 3c, online resource). In accordance with previously 
published results [63], ET-T42 showed lower affinity to bind 
microtubules than full-length Tau.
W‑Tau aggregation capacity in cultured cells
We compared the aggregation tendency of different Tau 
isoforms when overexpressed in HEK293T cells, by quanti-
fication of Tau in Sarkosyl soluble versus insoluble protein 
fractions, with the insoluble fraction including Tau aggre-
gates (Fig. 4a). With respect to full-length T42 aggregation 
capacity, we could observe that a similar soluble/aggregated 
protein ratio was found in full-length Tau isoforms. How-
ever, in truncated Tau isoforms, the ratio was different in 
W-Tau isoforms, with a higher proportion of soluble protein 
when compared to both full-length and ET-Tau isoforms, 
being significatively higher for W-T30 with respect to its 
correspondent full-length T30 (Fig. 3b, c). These results 
were further confirmed by means of a similar assay that 
tested solubility with Triton X-100 (Supplementary Fig. 4a, 
online resource). A similar analysis could be performed with 
the signal obtained from W-Tau antibody (Supplementary 
Fig. 4b, c, online resource).
In vitro aggregation of W‑Tau
In addition, we carried out the analysis of the formation of 
protein aggregates by in vitro incubation of purified T42, 
W-T42 and ET-T42 with heparin, observing a reduced pro-
portion of Tau aggregates when W-T42 was tested, com-
pared to the rest of the isoforms (Fig. 4d), as determined 
by densitometry of electrophoretically fractionated protein 
bands present upon centrifugation in supernatant (non-
aggregated protein) versus those present in pellet (aggre-
gated protein) (Fig. 4e). These results support that W-Tau 
displays diminished aggregation tendency.
Potential mechanism explaining intron 12 inclusion
We performed an in silico study, along with a bibliographic 
search, of the potential splicing factors involved in the pro-
cess. Results obtained with ESEFinder 3.0 indicate the pres-
ence of a high-scored SRSF6 splicing binding site in the 
canonical MAPT sequence, close to the beginning of Exon 
13 (Supplementary Fig. 5, online resource). This site is not 
present in the TIR-MAPT sequence. However, in its place, 
ESEFinder 3.0 indicates the appearance of a high-scored 
SRSF2 (also known as SC35) splicing binding site in intron 
12, in contrast to MAPT sequence splicing out intron 12 
(Supplementary Fig. 5, online resource). We re-analyzed 
MAPT exon 12–exon 13 and exon 12–intron 12 junction 
sequences using SRSF2 previously described binding sites 
[11, 38]. Surprisingly, we found that exon 12–intron 12 junc-
tion sequence, AGG TAA AG, is extremely similar to a spe-
cific SRSF2 binding site AGG TRA G (R for any Purine, A or 
G) previously described by Masaki et al. [38]. Both analyses 
suggested that SRSF2 may bind to TIR-MAPT sequence at 
the exon 12–intron 12 junction and/or at the beginning of 
intron 12 pointing to SRSF2 as a potential responsible for 
the regulation of this process. This evidence may be further 
supported by previous well-established evidence that SRSF2 
is also involved in Tau exon 10 splicing [29], pointing out a 
regulatory function of this splicing factor on Tau alternative 
splicing that may be linked to the intron retention described 
in this work.
Additionally, previous work of our group suggests that 
the inhibition of GSK3-mediated SRSF2 phosphorylation 
increases the inclusion of exon 10 [29]. Thus, we tested the 
effect of the inhibition of SRSF2 phosphorylation carried out 
by the constitutively active GSK3 kinase [29] on the reten-
tion of MAPT intron 12. We detected increased TIR-MAPT 
cytoplasmic mature RNA levels in SK-N-MC cells in the 
presence of the GSK3β inhibitor AR-014418 [7], compared 
to both untreated and amyloid β treated cells (Fig. 5a). When 
we analyzed W-Tau protein levels, we could observe that 
SB216763, other GSK3β inhibitor also results in increased 
W-Tau levels, although this increase is more relevant for 
AR-014418 (Fig. 5b). These preliminary data indicate that 
SRSF2 may be involved in this process via GSK3β regula-
tion (Fig. 5c).
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Finally, it is worth noting that the presence of beta amy-
loid peptide, that could stimulate GSK3 [28], did not result 
in a change in the level of neither TIR-MAPT nor W-Tau 
(Fig. 5a, b), probably because GSK3 is constitutively active 
and, therefore, amyloid-treated cells behave as untreated 
control cells containing already SC35 in its phosphorylated 
form. However, as previously described, amyloid β did result 
in a significant increase of total MAPT RNA (Fig. 5a).
Expression of TIR‑MAPT RNA in the brain of AD 
patients.
We studied TIR-MAPT mRNA levels in a cohort of hip-
pocampal brain samples from non-demented individu-
als and AD patients classified according to their Braak 
stage (see Supplementary Table 1, online resource). The 
study of absolute levels of TIR-MAPT mRNA revealed 
Fig. 6  TIR-MAPT RNA expression in the brains of AD patients. a 
Measurement of TIR-MAPT, b total MAPT and c TIR-MAPT/total 
MAPT ratio of RNA levels by RT-qPCR of non-demented (n = 8) 
and AD hippocampal samples (n = 16) classified according to their 
Braak stage (Braak II n = 3, Braak III n = 2, Braak V n = 7 and Braak 
VI n = 4), and healthy vs. AD patients. Graphs show means and SE. 
One-way ANOVA and Dunnett’s multiple comparisons test were per-
formed and statistical significance of each group with respect to non-
demented control individuals was given. For comparisons between 
non-demented individuals and AD patients as groups, p values were 
calculated using a T test (*p ≤ 0.05; ***p ≤ 0.001, †p = 0,078)
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that it slightly decreases in the first stages of the disease 
(Braak II and III) but increases in the advanced stages 
(Braak V and VI), although no significant differences 
were found (Fig. 6a). Total MAPT mRNA levels were 
similarly studied, finding in this case decreased expres-
sion in AD patients with respect to healthy individuals, 
more significantly in Braak stage VI (Fig.  6b). These 
data correlate with what we previously described in a 
human RNA-seq analysis [23]. Finally, when we studied 
TIR-MAPT/total MAPT ratio we could observe a signifi-
cant increase in Braak VI samples as well as a tendency 
towards an increased ratio in AD patients with respect to 
non-demented individuals (Fig. 6c).
Fig. 7  Tau protein determina-
tion in AD patients’ brain. 
a Immunodetection of the 
presence of W-Tau isoforms 
using W-Tau antibody in two 
different frontal lateral cortex 
brain extracts derived from AD 
patients’ brains (Braak V and 
VI, respectively). The immu-
noprecipitate performed with 
W-Tau antibody was character-
ized by Westernblotting. Left 
panel shows the blot developed 
using W-Tau antibody; right 
panel using Tau 7.51 antibody. 
b Western blot analysis of the 
levels of W-Tau and total Tau in 
frontal lateral cortical samples 
of non-demented (n = 9) and 
AD patients classified accord-
ing to their Braak stage (Braak 
I = 3; Braak II n = 6, Braak III 
n = 3, Braak IV n = 1, and Braak 
V n = 10, Braak VI n = 8). c 
Quantification of W-Tau and 
total Tau protein levels as well 
as W-Tau/total Tau ratio of each 
group. One-way ANOVA and 
Dunnett’s multiple comparisons 
test were performed and statisti-
cal significance of each group 
with respect to non-demented 
control individuals was 
given (*p ≤ 0.05; **p ≤ 0.01; 
***p ≤ 0.001; ****p ≤ 0.0001). 
A.U. arbitrary units
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W‑Tau presence in patients’ brains
Finally, in accordance to what was found for control human 
brains (Fig. 2d, e), we confirmed that W-Tau antibody was 
able to specifically immunoprecipitate W-Tau protein from 
human brain in extracts from AD patients (Braak stages V 
and VI) that could be identified as Tau again with a total Tau 
antibody (Tau 7.51) (Fig. 7a).
Once this was confirmed, we analyzed the levels of W-Tau 
protein in the cortex of healthy individuals and AD patients 
classified according to their Braak stage (Fig. 7b). We could 
observe that W-Tau is expressed in both healthy and AD 
individuals. The analysis of both W-Tau bands showed a 
strong diminished expression in all Braak stages with respect 
to non-demented individuals (Fig. 7c). Accordingly, the 
quantification of each W-Tau band separately also yielded 
significant differences in all Braak stages with respect to 
non-demented individuals (Supplementary Fig. 6a, online 
resource). On the other hand, the expression of total Tau 
seems to increase at later stages of the disease, but we 
could not detect significant differences among groups when 
individuals are separated by Braak stages in our samples 
(Fig. 7c). However, the ratio of W-Tau with respect to total 
Tau expression reveals an enrichment of W-Tau in advanced 
stages of the disease (Braak V and VI) (Fig. 7c).
Additionally, we could also obtain hippocampal samples 
of some of these individuals, and we studied W-Tau expres-
sion (Supplementary Fig. 6b, online resource). In such con-
ditions, similar to what we previously observed in Fig. 2d, 
e, we mainly detect 31 KDa (W-Tau truncated) and 50 KDa 
(W-T42) bands and, to a lesser extent, 38 KDa (W-T30) 
band. We could observe a trend towards diminished W-Tau 
expression in AD patients in the tree bands being significant 
in advanced stages of the disease for the 38 KDa (W-T30) 
band as well as in W-Tau/total Tau ratio (Supplementary 
Fig. 6c, d, online resource).
These data together indicate an inverse correlation 
between W-Tau levels and disease progression that opposes 
total Tau levels behavior, strongly suggesting a relevant role 
of this new intron-retaining isoform in healthy individuals, 
whose loss would be related to the progression of the dis-
ease. Taken RNA and protein data together (Figs. 6, 7) and 
considering the more marked presence of Tau aggregates in 
Total Tau but not in W-Tau, the changes on the amount of 
W-Tau in AD with respect to total Tau may be more related 
to differences on the protein turnover, rather than to their 
synthesis.
Discussion
Although recent evidence point out that a large proportion of 
predicted alternative transcripts might not be translated into 
proteins [55], MAPT gene has been proven to be genuinely 
subjected to alternative splicing [1, 55]. Also, MAPT con-
tains a cryptic exonic sequence codifying for the protein sai-
tohin nested in the Tau gene within intron 9 [14]. Thus, the 
removal of RNA sequences in Tau RNA is very usual, but 
the translation of intronic sequences could also take place. 
Curiously, it has been suggested that the region of “big” Tau 
corresponding to exon 4a arose, evolutionary, from an intron 
from another protein [20].
Tau alternative splicing is also regulated by several fea-
tures such as development, aging, disease or brain region 
[8, 54, 56, 58]. Tau isoforms lacking exons 2, 3 and 10, 
can be mainly found at early developmental stages [2, 56] 
and alternative splicing of exon 10 has been related to some 
tauopathies [10, 50].
Recently, a toxic fragment containing residues 1–368 has 
been reported [63]. Since residue 368 coincides with the end 
of exon 12, in this work we have studied whether a failure 
in the removal of intron 12 could give rise to a novel Tau 
isoform. We found that intron 12 retention can take place, in 
low proportions in non-demented human control as well as 
AD patients’ brains. The failure of intron 12 removal results 
in the appearance of a Tau isoform containing 18 additional 
residues after exon 12. Strikingly, this new isoform is sig-
nificantly reduced in AD, especially in the advanced stages, 
while total Tau is accumulated. It is worth emphasizing that 
this isoform is human-specific, since other species’ Tau 
orthologues do not contain the polyadenylation canonical 
site that allows intron retention to give rise to a truncated 
protein. This is especially noteworthy considering that Alz-
heimer’s disease is a human pathology that is not well repro-
duced in animal models.
A possible mechanism explaining intron 12 retention 
is that trans-acting splicing factors could be modified, for 
example by phosphorylation, and that the modified factor 
could change its function. Moreover, modification of intron 
splicing has been previously reported for SR-proteins [40] 
and, specifically, for SRSF2 (SC35) which, when phospho-
rylated by GSK3 kinase, favors the expression of Tau 3R 
(lacking exon 10) [29]. Additionally, it has been described 
that the absence of SRSF2 favors exon 10 inclusion increas-
ing Tau 4R species [12]. Notably, intron splicing events 
have been previously reported for SRSF2 and other mem-
ber of the SR-proteins family [40]. In this work, we found 
that GSK3 inhibition also induces the retention of intron 12, 
presumably by the inhibition of SRSF2 function, inducing 
the expression of TIR-MAPT mRNA and protein, while total 
Tau levels remain unmodified. SRSF2 could play a role in 
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this process, since there are two open recognition sites for 
this factor in TIR-MAPT sequence, one of them located at the 
exon 12–intron 12 junction [11, 38]. Of note, W-Tau levels 
did not change in amyloid-treated cultured cells, even though 
amyloid beta peptide has been reported to stimulate GSK3 
[12, 28]. This may be due to GSK3 being constitutively 
active and, consequently, amyloid-mediated activation does 
not imply further SRSF2 phosphorylation when comparison 
to untreated cells.
The novel Tau fragment described in this work is very 
similar to the previously reported fragment generated 
by cleavage of AEP [63]. However, contrary to what was 
expected, the isoforms truncated by intron retention exhibit 
a potentially protective behavior, with decreased aggregation 
capacity but conservation of microtubule assembly capac-
ity. This novel Tau isoforms contain a unique 18-aminoacid 
extra peptide, including the sequence GVGWVG, which 
could be similar in nature to that of LYIWVQ, a recently 
described inhibitor of Tau and Aβ aggregation [27] (Supple-
mentary Fig. 7, online resource). Thus, we suggest that the 
decreased aggregation capacity of W-Tau could be related 
to the presence of this extra peptide. Moreover, W-Tau 
lacks the 12 amino acids after the fourth repeat, present in 
exon 13, which are found in the core of Tau filaments iso-
lated from the brain of patients suffering some tauopathies, 
including Alzheimer’s disease [62]. It is also worth noting 
that the specific W-Tau 18 amino acid sequence contains 
two adjacent cysteines (KKVKGVGWVGCCPWVYGH), 
whose oxidation to cystine can mediate the formation of a 
strained eight-member ring [47], a conformation that would 
substantially differ of that of other Tau isoforms and that 
has been proposed to be able to affect protein function and 
conformation stability [33, 39].
As for the relevance of this novel truncated isoform in 
AD’s development and progression, similar TIR-MAPT 
mRNA levels were found in non-demented control subjects 
and AD patients’ samples. However, on a protein level, we 
have detected higher levels of W-Tau protein in healthy 
individuals compared to AD patients. Discordant RNA and 
protein levels for Tau in AD have been previously described 
[23]. We hypothesize that, in this case, it may be related 
to a relatively faster turnover for W-Tau isoforms, maybe 
linked to a different conformation rising from its different 
sequence. These data also showed a clearly less aggrega-
tive pattern on W-Tau isoforms when compared to total Tau 
(Fig. 7), suggesting that this is a less aggregation-prone Tau 
isoform indeed.
Finally, therapeutic correction of aberrant splicing that 
could take place in Alzheimer’s disease has been suggested 
for some nuclear RNAs [4, 31]. Given the potential role of 
this new Tau truncated isoform on a possible AD therapy, 
we will look for future therapeutic strategies based on an 
increase of this less aggregation-prone Tau isoform or the 
prevention of its decrease.
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